Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP policies and guidelines news

Show

From To
A Review of the Congressional Hearing on HIV Drug Pricing

In an effort to best encapsulate the remarks of many of the members of the House and the powerful testimony of the HIV advocates present at the recent Congressional hearing on drug pricing around Gilead Sciences’ HIV prevention drug Truvada, we thought it was best to provide you with their own words.

Published
23 hours ago
From
POZ
Republicans defend drug company in spotlight over HIV medication prices

Republican members of Congress defended Gilead, the leading manufacturer of HIV drugs in the U.S., during a testy hearing Thursday as Democrats blasted the company over the prices of its products.

Published
17 May 2019
From
The Hill
A Leading HIV Drug Is Way Overpriced in the U.S.

A House hearing over the price of Truvada shows a particularly glaring example of a rampant industry practice.

Published
17 May 2019
From
Bloomberg
Alexandria Ocasio-Cortez Tells Gilead CEO That ‘People Are Dying’ Because His Company Charges Nearly $2,000 For Drug That Sells For $8 In Australia

"I think it's important here that we notice that we the public, we the people, developed this drug. We paid for this drug, we led and developed all the patents to create PrEP [the commonly known name for Truvada] and then that patent has been privatized, despite the fact that the patent is owned by the public, who refused to enforce it," the representative said. “There’s no reason this should be $2,000 a month. People are dying because of it,” she added.

Published
17 May 2019
From
Newsweek
Statement on Gilead’s Announcement of PrEP Donation

Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.

Published
14 May 2019
From
AVAC
Five Reasons the Gilead Giveaway is a Steaming Pile of Truvada

Gilead is engaged in a brilliantly self-serving marketing ploy and dressing it up like charity.

Published
12 May 2019
From
My Fabulous Disease
Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study

One of the most sobering posters at BHIVA 2019 was able to directly link recent HIV infections to the NHS block on access to PrEP.

Published
10 May 2019
From
HIV i-Base
Generic PrEP to Arrive in September 2020, but Will Big Savings Follow?

Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.

Published
10 May 2019
From
Poz
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

Officials at the Department of Health and Human Services said the donation came about “as a result of discussions between the Trump administration and Gilead.” Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.

Published
10 May 2019
From
The New York Times
PrEP 2-1-1 offered at Magnet, San Francisco

For the first time in the U.S., PrEP “on-demand” dosing is being offered routinely at the San Francisco AIDS Foundation sexual health clinic Magnet.

Published
08 May 2019
From
BETA blog
← First12345...11Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.